Now I have a solid calibration. Let me write the consolidated review.

## Summary
This paper evaluates small language models (SLMs, ≤3B params) against larger domain-adapted LLMs (7–8B) on clinical text summarization and radiology report generation, using both in-context learning and parameter-efficient fine-tuning. It claims that LoRA-tuned 1B LMs can match or exceed larger medical LLMs on summarization metrics, and introduces a "collapse analysis" identifying a safety threshold around 1B parameters below which hallucination rates spike. For radiology VLMs, it finds small models lag behind larger ones even after fine-tuning.

## Strengths

- **Fair zero-shot benchmark (Table 2).** Under identical zero-shot evaluation across five prompt templates, SmolLM2 (1.7B) achieves competitive BERTScore (0.9007) and MEDCON (0.271) against BioMistral-7B, Med-LLaMA-8B, and OpenBioLLM-8B. This comparison is symmetric and provides genuine evidence that smaller models can hold their own on semantic and concept-level metrics without task-specific adaptation.

- **Prompt sensitivity is acknowledged and mitigated.** The paper averages results across five instruction variants for zero-shot evaluation (Section 3.1) and reports prompt robustness scores in the collapse analysis. This is a more rigorous approach than fixing a single prompt and demonstrates awareness of a known vulnerability in LLM evaluation.

- **Clean negative result for vision-language models (Table 4).** After fine-tuning on 10K MIMIC-CXR pairs, small VLMs (Florence 2, Qwen2.5-VL) remain below Med-Flamingo and LLaVA-Med on all metrics. This finding — that the visual domain still demands larger capacity even after task-specific adaptation — provides an informative counterpoint to the text summarization results and helps scope when small models are appropriate.

- **The "safety collapse" concept is practically motivated.** The idea of identifying a minimum viable scale for trustworthy clinical deployment addresses a real need in on-premise healthcare AI. The general framing — that quality degrades non-uniformly below a threshold — is useful even if the present operationalization has gaps.

## Weaknesses

### Major

- **Asymmetric comparison undermines the headline claim.** The paper's central finding — "all small LMs outperformed large LMs across every metric" (Section 4, echoed in abstract and conclusion) — compares **LoRA-fine-tuned small models** against **in-context-learning (2-shot) large models**. Large models are given no opportunity for task-specific adaptation. This is visible in Figure 3, where large models have no LoRA bar; the caption confirms the asymmetry. The claim as stated conflates the benefit of fine-tuning with an architectural efficiency advantage. A reframed conclusion — "LoRA-tuned small LMs can outperform ICL-based large LMs" — is far less surprising and does not support the paper's broader narrative about model size not being a barrier. The abstract and introduction present the finding in general terms without caveating this asymmetry, which is misleading. The paper *has* a fair zero-shot comparison (Table 2) where small models are competitive but do not consistently dominate — but this is not the claim that receives emphasis.

- **Collapse analysis metrics are unsubstantiated (Table 3).** The paper introduces four dimensions — Task Adherence, Hallucination Rate, Clinical Concept Recall, Prompt Robustness — plus a composite Readiness Score, but never specifies how any of these are measured. No annotation protocol, rubric, automatic metric, or derivation formula is provided. The numbers in Table 3 are presented as factual findings (e.g., "hallucination rates spike from ≤3.5% to 18–75%"), yet the reader cannot interpret, reproduce, or verify them. This is not a minor documentation gap: the collapse analysis is positioned as a signature contribution (it appears in the abstract, contributions list, and Findings 1), and claims about clinical safety thresholds rest on it. Without measurement methodology, these results are unverifiable.

### Minor

- **Radiology comparison fairness is ambiguous.** After fine-tuning small VLMs on 10K MIMIC-CXR pairs, the paper compares them against Med-Flamingo (9B) and LLaVA-Med v1.5 (7B) (Table 4). It does not state whether these large VLMs were also fine-tuned on the same data or evaluated zero-shot. If the large models were not fine-tuned, the comparison is again asymmetric, and the conclusion that "small VLMs lag behind large ones" would need re-evaluation under equal adaptation conditions. The paper should explicitly clarify the adaptation mode of each model in Table 4.

- **No confidence intervals or significance tests.** All results are point estimates over 250 test samples. Without measures of variance, the reader cannot assess whether observed differences between models are meaningful or within noise. This is particularly relevant for claims that a specific model "surpasses" another on metrics like BLEU and ROUGE-L, where differences may be small.

- **No clinical expert evaluation.** The paper draws conclusions about clinical safety ("safety collapse," "minimum viable scale for trustworthy clinical deployment") but relies entirely on automated metrics (BLEU, ROUGE, BERTScore, MEDCON). These do not measure whether a summary is clinically usable or safe. A small human evaluation — even a handful of cases assessed by medical professionals — would substantially strengthen the practical claims, especially given the severe thresholds claimed (75% hallucination rates).

- **The limitations section does not acknowledge the asymmetric comparison.** The limitations mention computational constraints and scope but do not note that large models were not fine-tuned. This omission means the discussion does not help readers calibrate the strength of the main finding.

### Trivial

- Table references in the radiology section are broken ("Table ??") — a formatting artifact.
- Figure 3 caption is dense and hard to parse; the asymmetry between ICL and LoRA treatments for small vs. large models is not called out.

## Nice-to-Haves
- Fine-tuning the large LMs with LoRA on the same data would directly test whether the observed advantage is due to fine-tuning or to small-model efficiency.
- Defining the collapse analysis metrics — even via simple heuristic rules or LLM-as-judge ratings with inter-rater agreement — would make Table 3 reproducible and the safety-collapse claim testable.
- Reporting confidence intervals or bootstrap estimates would help assess the reliability of the observed gaps.

## Removed Points

- **"Both top-k and top-p used together is unusual"** (Harsh Critic point). This is common practice in HuggingFace transformers (top-p is applied after top-k filtering) and is not a methodological issue. REMOVED.
- **"Strength: LoRA-tuned 1B LMs surpass 7–8B medical LLMs"** (Strength Finder #1). This conflicts with the verified weakness about asymmetric comparison. REMOVED.
- **"Strength: Quantitative safety-collapse threshold below ~1B"** (Strength Finder #2). This conflicts with the verified weakness about unsubstantiated collapse metrics. REMOVED.
- **"Strength: Multi-dimensional evaluation framework"** (Strength Finder #3). Same issue — the framework is introduced but its metrics are undefined. REMOVED.
- **"Missing related works"** (inferred from context). Rule prohibits mentioning missing related works as a weakness. REMOVED.
- **Reproducibility nitpicks about undisclosed hyperparameters or training logs** (mentioned by Harsh Critic). Rule prohibits these as weaknesses. REMOVED.
- **"The evaluation of 250 test samples is small"** — incorporated into the Minor weakness about confidence intervals rather than as a standalone criticism. WEAKENED from what the Harsh Critic implied.
- **"Few-shot prompting can obscure prompt engineering effects"** — the paper explicitly averages across five prompts to mitigate this, so the concern is addressed. REMOVED.

## Novel Insights
None beyond the paper's own contributions.

## Suggestions
1. **Reframe the central claim.** Clearly distinguish between the fair zero-shot comparison (where small models are competitive) and the asymmetric fine-tuned-vs-ICL comparison. If the latter is presented at all, it must be qualified as "LoRA-tuned small models vs. ICL-only large models." Better yet, fine-tune the large models under the same LoRA protocol to enable a symmetric comparison.
2. **Define the collapse analysis methodology.** Provide an explicit account of how Task Adherence, Hallucination Rate, Concept Recall, Prompt Robustness, and the Readiness Score are computed. If automated, describe the heuristic or LLM-based pipeline; if human-rated, report the rubric and inter-annotator agreement.
3. **Clarify the VLM comparison.** State explicitly whether Med-Flamingo and LLaVA-Med were fine-tuned or used zero-shot/few-shot, and discuss how the adaptation mode affects interpretation.
4. **Add variance estimates.** Report confidence intervals or bootstrap ranges for all metrics, especially where the paper claims one model "exceeds" or "surpasses" another.

## Score and Decision

**Round 1 bracketing (3 queries, all on "small language models clinical text summarization evaluation"):**
- Low anchors (avg < 3.5): scores 2.0–3.0 — papers that are topically related but weak. Our paper is stronger than these.
- Middle anchors (3.5 < avg < 7.5): scores 3.75–6.00 — includes papers on clinical LLM evaluation at various quality levels.
- High anchors (avg > 7.5): scores 8.0–8.5 — papers on training dynamics, sampling methods, evaluation methodology. Our paper does not belong in this band.

**Round 1 bracket:** 3.5–5.5

**Round 2 narrowing (anchors in (3.0, 5.5) and (4.5, 6.5)):**
- Rejected papers at 4.0–4.33 (fictional medical MCQs, scaling effects, clinical knowledge assessment) share a profile with our paper: interesting question, but significant methodological issues that prevent reliable conclusions.
- Accepted/mixed papers at 5.5–6.0 (ClinicalBench, Enhancing Small Medical Learners, Cost of Scaling Down) have clearer methodology, fair comparisons, and substantiated claims.
- Our paper's two major issues (asymmetric comparison, undefined metrics) place it clearly below these 5.5–6.0 papers. It is most comparable to the 4.0–4.33 cluster.

**Final score: 4.0.** The paper addresses a relevant question and has some useful individual results (Table 2 zero-shot benchmark, Table 4 VLM comparison). However, the two major weaknesses — an asymmetric evaluation that invalidates the headline claim, and an unsubstantiated collapse analysis that is presented as a core contribution — prevent the paper from providing a reliable answer to its own question. The contributions as currently executed are not commensurate with the strength of the claims.

**Decision: Reject**

MY FINAL SCORE: <score>4.0</score>
MY FINAL DECISION: <decision>Reject</decision>